|Product Overview:||Recombinant Human SLAMF6(Gln22-Met226) fused with His tag at C-terminal was expressed in HEK293.|
|Description:||NTB-A, also known as Ly108 and SLAMF6, is a 60 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family. Mature human NTB-A consists of a 205 amino acid (aa) extracellular domain (ECD) with one Ig-like V-set and one Ig-like C2-set domain, a 21 aa transmembrane segment, and an 84 aa cytoplasmic domain with two immunoreceptor tyrosine-based switch motifs (ITSMs). An alternatively spliced isoform is truncated in the cytoplasmic domain and lacks the two ITSMs. Within the ECD, human NTB-A shares 48% aa sequence identity with mouse and rat NTB-A. The ECD of human NTB-A shares 19%-34% aa sequence identity with comparable regions of human 2B4, BLAME, CD2F-10, CD84, CD229, CRACC, and SLAM. NTB-A is expressed on the surface of NK, T, and B lymphocytes as well as eosinophils. It interacts homophilically through weak associations between the Ig-V domains. NTB-A functions as an activating coreceptor on NK and T cells. Tyrosine phosphorylation in the membrane proximal ITSM enables specific association with EAT-2, an interaction that is required for NTB-A mediated cytotoxicity of NK cells. Phosphorylation-dependent NTB-A association with SAP is required for full production of IFN-gamma by NK cells. This interaction is independent of EAT-2 binding and appears to involve the membrane distal ITSM. NTB-A deficient mice show weakened Th2 responses and elevated levels of neutrophil-derived inflammatory mediators. In B cells, NTB-A modulates immunoglobulin class switching and the balance between tolerance and autoimmunity. In addition, NTB-A binds to the influenza virus hemagglutinin (HA) protein which co-stimulates NK cell activation. The Vpu protein encoded by HIV-1 interferes with NTB-A glycosylation and cell surface expression.|
|Predicted N Terminal:||No results obtained. Gln22 inferred from enzymatic pyroglutamate treatment revealing Ser23|
|Form:||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Bio-activity:||Measured by its binding ability in a functional ELISA. When Recombinant Human NTB-A/SLAMF6 is coated at 1 μg/mL (100 μL/well), the concentration of Biotinylated Recombinant Human NTB-A/SLAMF6 Fc Chimera that produces 50% optimal binding response is 0.6-3 μg/mL.|
|Molecular Mass:||Predicted Molecular Mass: 24 kDa
SDS-PAGE: 34-42 kDa, reducing conditions
|Endotoxin:||<0.1 EU per 1 μg of the protein by the LAL method.|
|Purity:||>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.|
|Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -70 centigrade as supplied.
6 months, -70 centigrade under sterile conditions after opening.
|Reconstitution:||Reconstitute at 500 μg/mL in PBS.|
|Gene Name:||SLAMF6 SLAM family member 6 [ Homo sapiens ]|
|Synonyms:||SLAMF6; SLAM family member 6; CD352; KALI; KALIb; Ly108; NTB A; NTBA; SF2000; NTBA receptor; NK-T-B-antigen; activating NK receptor; natural killer-, T- and B-cell antigen; NTB-A; FLJ50657; MGC104953;|
Price does not include shipping and packaging costs.Request quote for final price.